Salignostics

Salignostics Overview

Salignostics develops fast, safe, user-friendly, and cost-effective saliva-based diagnostic solutions. Its cutting-edge technology processes saliva into an analyzable body fluid, offering fast, safe, user-friendly, and cost-effective diagnostic options for self-testing, homecare, point-of-care, and laboratory settings. This addresses the limitations of current diagnostic methods which are expensive, time-consuming, and personnel dependent. Our products facilitate easy saliva self-collection, sample preparation, and rapid detection of a wide array of analytes and biomarkers in a single device. The device can identify human proteins, viral proteins, DNA, and RNA, with the ability to detect a high number of previously unidentifiable biomarkers. This enables non-invasive and painless diagnostics at home. Salignostics holds 4 innovative patents and 2 trade secrets covering its platform technology. The possibility to collect, detect, and test positions us to address a large group of multi-billion-dollar markets, including the home diagnostics market, projected to grow to $10B by 2032. In 2023, we have successfully launched Salistick, the first rapid saliva-based pregnancy test, already available in the UK, Sweden, and Israel. Salignostics plans to reach $70M annual revenues by 2030, through expanding its product reach, developing new saliva-based diagnostic applications, and establishing R&D and commercial collaborations with global diagnostics companies.

Cumulative Funding Raised Over Time ($)

Latest News

May 28, 2024 · nocamels.com

growth-positive

Startup, Sheba Developing Saliva Test For Mouth Cancers

Jerusalem-based startup Salignostics is partnering with ARC, the innovation department of Sheba Medical Center, to develop a saliva-based diagnostic tool for oral cavity cancer. This will be the first saliva-based diagnostic tool for cancer. The test aims to address the lack of an effective early detection tool for oral cavity cancer, which has a five-year survival rate of just 50%. The team plans to explore the potential for diagnosing other cancers once they have established proof of concept.

Partners

Aug 14, 2023 · www.abingdonhealth.com

growth-positive

Salistick™, the first ever saliva pregnancy test, to be launched in Tesco - Abingdon Health plc

Abingdon Health plc has announced that Tesco will roll out Salistick, the first-ever saliva pregnancy test, in 298 stores and online from late-August 2023. This follows the initial launch of Salistick with Superdrug in 400 stores. The Salistick pregnancy test offers an improved user experience, with high accuracy for early pregnancy detection. Abingdon Health is the exclusive distributor of Salistick in the UK and Ireland on behalf of Salignostics Limited, an Israeli developer of innovative saliva-based diagnostics tests.

CustomersPartnersExpand

Jul 11, 2023 · www.calcalistech.com

growth-positive

Hagai Dror appointed as Chief Strategy and Business Development Officer at Salignostics | CTech

Hagai Dror, a former senior official at the Israeli Ministry of Health, has been appointed as Chief Strategy and Business Development Officer at Jerusalem-based startup Salignostics. The company specializes in the development and supply of rapid tests based on saliva samples for early detection of various diseases. Dror brings extensive experience to the role, having served in various positions within the health ministry. Salignostics was founded in 2016 and has raised $20 million to date, including $8 million in Series A funding from a group of private angel investors led by Avigdor Orlinsky.

Management ChangesInvestment

Apr 13, 2022 · www.israelhayom.com

https://www.israelhayom.com/2022/04/13/israeli-saliva-based-diagnostics-startup-raises-8m-in-series-a/

Apr 13, 2022 · www.themarker.com

growth-positive

נולדה בישראל: בדיקת ההריון המהירה הראשונה בעולם באמצעות רוק

Israeli startup, Seligentics, has developed the worlds first rapid pregnancy test using saliva samples. The test detects physiological conditions and has paved the way for the development of a line of rapid home tests. The company is now starting commercial production after establishing a manufacturing facility with an investment of around $2.5 million. The facility includes robots and advanced equipment for accurate testing. The founders, four doctors and a professor, split their time between Jerusalem and the Galilee. The article highlights the innovative nature of the test and the potential impact it can have on the market.

Expand

Funding

Team Members

6

Employees: 11-50

Web & Social Links

Locations

Ein Karem, Jerusalem, Israel

Photos & Videos

3 item(s)

Salignostics Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info